Terry Tormey
Terrence “Terry” Tormey is CEO at Kibow Biotech, Inc., Pennsylvania, a 21-year old R&D company, which is arguably the pioneering company focused on the Gut Microbiome for a variety of serious illnesses.
Having launched and/or supported dozens of Rx products and scores of non-prescription products Mr. Tormey is an expert in Healthcare Marketing within the US and Global BioPharma Industry.
Ted Jin
Sunny Jain
With over 20 years of Molecular and Microbiology experience, Sun Genomics’ founder and CEO Sunny Jain originally had the idea for Floré after struggling to solve his own young son’s gut health issues with generic probiotics from the shelves. Sunny took it upon himself to create a custom probiotic that worked for his son, and now aims to do the same for the hundreds of millions of people who suffer from gut health issues worldwide.
Before starting Sun Genomics, Sunny worked at Illumina for seven years. He was part of the team to establish the Illumina Clinical Services Laboratory and went on to sequence the first whole human genome in a CLIA-certified, CAP-accredited laboratory. Prior to Illumina, Sunny worked for Labcorp in the molecular oncology laboratory and has over 20 years of experience in commercializing biomarkers.
Sean O'Sullivan
Sean O’Sullivan is managing partner of SOSV, the world-leading “Accelerator VC”. SOSV invests $50 million per year and backs more than 150 new startups annually through its accelerators. Recognized in 2017 as the world’s #1 most active global early stage investor and the #2 most active global seed investor*, SOSV is also the #1 most active investor in hardware and life sciences, helping startups get further and go faster.
* Crunchbase: "Global Innovation Investment Report - 2016 Year in Review"
Richard Cleland
Mr. Cleland joined the Federal Trade Commission’s Division of Advertising Practices in 1991. In 1996, Mr. Cleland was appointed Assistant to the Director of the Bureau of Consumer Protection and, in 1998, he was appointed Assistant Director of the Division of Service Industry Practices.
He currently serves as Assistant Director of the Division of Advertising Practices. His primary area of expertise is the advertising and marketing of health-related products and services. He also supervises many of the Commission’s health fraud and weight-loss product and service law enforcement initiatives.
Mr. Cleland supervised the FTC’s review of the Endorsement and Testimonial Guides and the revision of the FTC’s guidance on making effective disclosures on the Internet and other digital platforms (.com Disclosures). Recent projects have included social media marketing and native advertising.
Rend Al-Mondhiry
Rend Al-Mondhiry advises the dietary supplement, food, cosmetic, and over-the-counter medicine industries on a broad range of regulatory and compliance matters. She is committed to helping companies responsibly develop and market products, drawing on her years of experience advising the nation’s leading dietary supplement and food companies on complex ingredient and labeling issues.
Rend’s practice focuses on reviewing product labeling, ingredients, and advertising to determine compliance with federal and state regulations, and assisting companies in matters before the Food and Drug Administration (FDA), Federal Trade Commission (FTC), and National Adverting Division (NAD). She also advises clients on compliance with California’s Proposition 65, U.S. Customs issues, class action defense strategies, and FDA matters including Warning Letters, recalls, detentions, seizures, and import alerts.
Noah Voreadas
Nalin Siriwardhana
Mike Rogers
Michael Bush
Mike has more than 25 years of experience leading venture-backed businesses in the natural products, healthcare and bioinformatics industries. As president and CEO of probiotic innovator Ganeden, Michael grew the market of the company’s patented ingredient to over 65 countries and more than 1,000 SKUS, culminating with the 2017 merger with Kerry, Inc. Additionally, he founded a national business growth consultancy firm, co-founded a national biomedical services firm and led acquisitions and merger activities for a global medical services company.